48 completed, 15 active not recruiting, 13 recruiting, 10 unknown. 53 Phase 2, 20 Phase 1, 17 Phase 3, 13 Not applicable, 12 Early Phase 1.
Follow gallium 68 PSMA-11: new trials by email Literature Review of gallium 68 PSMA-11 trials Research Report on gallium 68 PSMA-11
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-12-01 | 2026-10-15 |
| Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer | Early Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 30 | 2026-10-01 | 2026-08-24 |
| 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions - Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer | Not applicable | Not yet recruiting | University Health Network, Toronto | 8 | 2026-09-01 | 2026-08-05 |
| Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC AAA602, AAA802, Gallium (68Ga) gozetotide - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-29 | 2025-12-29 | |
| An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11 - WHO Grade 3 Glioma, WHO Grade 4 Glioma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2026-01-12 | 2026-06-22 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| PSMA PET Combined With MRI for the Detection of PCa 68Ga-PSMA-11 - PCA, Prostate Cancer | Phase 3 | Active not recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 338 | 2025-08-18 | 2026-10-20 |
| Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma [68Ga]Ga-DOTA-CAIX peptide, [68Ga]Ga-NOTA-CD70 antibody fragment, [68Ga]Ga-PSMA - Renal Cell Carcinoma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 66 | 2025-06-01 | 2025-12-24 |
| Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer 225Ac-LNC1011, 68Ga-PSMA-11 - Prostate Cancer | Phase 2 | Active not recruiting | First Affiliated Hospital of Fujian Medical University | 24 | 2025-04-22 | 2026-10-23 |
| Preoperative Planning With PSMA-PET in Melanoma Surgery Trial 68Ga-PSMA - Malignant Melanoma | Phase 2 | Recruiting | Royal Marsden NHS Foundation Trust | 16 | 2025-03-11 | 2025-07-01 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11 - Metastatic Adenoid Cystic Carcinoma | Phase 2 | Completed | Mayo Clinic | 6 | 2024-08-12 | 2025-09-12 |
| Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 40 | 2024-08-01 | 2026-03-13 |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan - Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 90 | 2024-08-01 | 2026-03-10 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB - Metastatic Neuroendocrine Prostate Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 31 | 2024-07-29 | 2026-10-15 |
| Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Clinical Observation - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Suspended | Mayo Clinic | 236 | 2024-05-03 | 2026-08-20 |
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function AAA617, 68Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 23 | 2024-04-04 | 2026-07-10 |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial Apalutamide, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 95 | 2024-03-28 | 2026-07-17 |
| PSMA PET Response Guided SabR in High Risk Pca 68-Ga PSMA11 - Prostate Adenocarcinoma | Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 20 | 2024-03-07 | 2026-04-14 |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC AAA617, AAA517, Piflufolastat F 18 - Prostatic Neoplasm | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 49 | 2024-01-03 | 2026-10-21 |
Showing 20 of 111. Sign in to see all of them.
Prostatic Neoplasms (84) · Carcinoma, Hepatocellular (4) · Carcinoma, Renal Cell (3) · Neoplasms (3) · Adenocarcinoma (2) · Carcinoma, Adenoid Cystic (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Prostatic Diseases (2) · Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Genital Diseases, Male (1)
Jonsson Comprehensive Cancer Center (14) · Mayo Clinic (9) · Novartis Pharmaceuticals (9) · Weill Medical College of Cornell University (6) · Andrei Iagaru (5) · University of California, San Francisco (5) · Peking Union Medical College Hospital (4) · Thomas Hope (4) · Chang Gung Memorial Hospital (3) · Dana Mathews (3) · First Affiliated Hospital of Fujian Medical University (3) · Emory University (2) · IRCCS San Raffaele (2) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) · Sir Mortimer B. Davis - Jewish General Hospital (2)
United States (75) · China (13) · Canada (8) · Italy (7) · France (6) · Germany (6) · Spain (5) · Austria (4) · Taiwan (4) · United Kingdom (4) · Australia (3) · Belgium (3) · Czechia (3) · Poland (3) · Switzerland (3)
Jeremie Calais (5) · Thomas Hope, MD (5) · Scott Tagawa, MD (4) · Andrei H Iagaru, MD (3) · Jeremie Calais, MD (3) · Orhan K Oz, MD, PhD (3) · Zhaohui Zhu, MD (3) · Ajit H. Goenka, M.D. (2) · Amar Kishan (2) · Andrei Iagaru (2) · Brian J. Burkett, MD, MPH (2) · Jing-Ren Tseng, MD (2) · Michael Repka, MD (2) · Morand R Piert, M.D. (2)
PMID 41698328, PMID 33465252, PMID 34529005, PMID 37482512, PMID 30920593, PMID 31375469, PMID 32808077, PMID 33602654, PMID 34326126, PMID 36512649, PMID 1289676, PMID 15493005, PMID 18207194, PMID 18325358, PMID 21149473, PMID 22369515, PMID 23041906, PMID 24072344, PMID 24207135, PMID 25598074, PMID 25883127, PMID 26116124, PMID 26294298, PMID 26334122, PMID 26361169, PMID 26659347, PMID 26681984, PMID 27609792, PMID 28267452, PMID 28522741, PMID 29129779, PMID 29242398, PMID 29242404, PMID 29786490, PMID 30616601, PMID 31039025, PMID 32958451, PMID 33025093, PMID 33034050, PMID 33341915, PMID 33386288, PMID 33620559, PMID 33674398, PMID 34406051, PMID 34649942, PMID 34725726, PMID 34783177, PMID 35984529, PMID 35985901, PMID 36328488
2023 (4), P30CA138292 (2), 2015 (1), 2016 (1), P30CA033572 (1), P30CA124435 (1), R01CA207645 (1), R01CA226992 (1), R01CA230438 (1), R01CA289631 (1), R37CA286450 (1), R44CA239461 (1)